Diplomat’s Taltz approved for treatment of plaque psoriasis

Diplomat’s Taltz approved for treatment of plaque psoriasis

April 5, 2016 Off By Dino Mustafić
gary-kadlec

Gary Kadlec

TALTZ was recently approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe plaque psoriasis.

To learn more about Diplomat’s psoriasis program, click here.

Psoriasis is an autoimmune condition that affects the skin, causing patches of redness and irritation. The condition occurs more often in patients with a family history of the disease, with symptoms typically starting between the ages of 15 and 35. The most common form is plaque psoriasis; patients with this form develop raised, red patches of skin covered with a silvery-white layer of dead skin cells.

“Psoriasis is a serious chronic disease that can have debilitating symptoms,” said Gary Kadlec, Diplomat president. “TALTZ enables patients an important treatment option.”

TALTZ is indicated for the treatment of of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy or phototherapy.

TALTZ is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.